Investigating how tissue damage leads to a specific type of skin cancer.
Tissue Damage-Driven Squamous Cell Carcinoma
This study is looking at how skin cancer, specifically squamous cell carcinoma, affects people with a rare genetic condition called Recessive Dystrophic Epidermolysis Bullosa, to find out what causes the cancer to grow and worsen, so we can discover better ways to treat it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11001219 on NIH RePORTER |
What this research studies
This research focuses on squamous cell carcinoma (SCC), a type of skin cancer that can be deadly, particularly in patients with the genetic condition Recessive Dystrophic Epidermolysis Bullosa (RDEB). The study aims to understand the genetic and environmental factors that contribute to the development and progression of SCC in these patients. By analyzing the tumor microenvironment and gene expression patterns, researchers hope to identify common mechanisms that lead to poor outcomes in SCC. This could provide insights into better treatment strategies for patients suffering from this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Recessive Dystrophic Epidermolysis Bullosa who are at risk of developing squamous cell carcinoma.
Not a fit: Patients with squamous cell carcinoma not associated with Recessive Dystrophic Epidermolysis Bullosa may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for patients with squamous cell carcinoma, particularly those with RDEB.
How similar studies have performed: Other research has shown promising results in understanding the mechanisms of squamous cell carcinoma, but this specific approach focusing on RDEB is relatively novel.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: South, Andrew — Thomas Jefferson University
- Study coordinator: South, Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.